Current and Novel Therapies for Mantle Cell Lymphoma CME

Author Information and Disclosures

Release Date: March 11, 2008; Valid for credit through March 11, 2009

Credits Available
Physicians - maximum of 1.25 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 Medscape.
WebMD
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Describe the clinical features and epidemiology of MCL as well as key diagnostic issues
  2. Evaluate the efficacy and safety of current options for the treatment of patients with MCL in the front-line setting and in patients who relapse
  3. Examine preliminary findings regarding the use of various new investigational therapeutic approaches for the treatment of MCL, including mTOR inhibitors, Bcl-2 inhibitors, novel antibodies, and others
Authors and Disclosures

Thomas E. Witzig, MD
Disclosure: Thomas E. Witzig, MD, has disclosed that he has received grants for clinical trials from Novartis and Wyeth and has served on the advisory boards for Cephalon, Novartis, and Wyeth.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.